Crossmark

A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity

Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P124

Published Online: 2015-11-04

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Garrett, Tracy E

Chekmasova, Alena A

Evans, John W

Seidel, Stacie L

Horton, Holly M

Latimer, Howard J

Griecci, Johanna A

Horvath, Christopher J

Ryu, Byoung Y

Friedman, Kevin M

Morgan, Richard A
More Information

Article History

First Online: 4 November 2015